Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05867914 · ClinicalTrials.gov registry record · NA
Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD
A NA study of Lung Diseases, Interstitial and Hypertension, Pulmonary, sponsored by Third Pole Therapeutics.
- Active
- Registry status
- NA
- Development phase
- 5
- Enrollment target
- 3
- Study locations
NCT05867914: Active NA study of Lung Diseases, Interstitial and Hypertension, Pulmonary, sponsored by Third Pole Therapeutics.
NCT05867914 is a NA study of Lung Diseases, Interstitial and Hypertension, Pulmonary that is active but no longer recruiting, run by Third Pole Therapeutics. The registered enrollment target is 5 participants, below the 12,508-participant average among 10 other Lung Diseases, Interstitial trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05867914, a NA study of Lung Diseases, Interstitial and Hypertension, Pulmonary, is active but no longer recruiting, sponsored by Third Pole Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
- 3
- Study locations
Study Summary
A trial to evaluate the safety, tolerability, and functionality of 3P-100, in subjects with Pulmonary Hypertension (PH) accompanying Interstitial Lung Disease (ILD), PH-ILD
Primary Outcome
Incidence of Adverse Events as assessed by CTCAE v5.0
Conditions Studied
Interventions
- DEVICE Inhaled Nitric Oxide (iNO)
Study Locations (3)
Florida
- TGH/USF Center for Advanced Lung Disease and Lung Transplant - Tampa
Ohio
- University of Cincinnati - Cincinnati
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-12-04 |
| Est. Completion | 2024-03-29 |
| Phase | NA |
What the registry record for NCT05867914 still lists
NCT05867914 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 12,508-participant average among 10 other Lung Diseases, Interstitial trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Lung Diseases, Interstitial appearing as the primary indexed condition, and to 1 intervention - of which Inhaled Nitric Oxide (iNO) is the first listed.
NCT05867914 reports a single indexed study location in Florida, Ohio, South Carolina.
Frequently Asked Questions
What is clinical trial NCT05867914 about?
NCT05867914 is a clinical study titled "Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD". A trial to evaluate the safety, tolerability, and functionality of 3P-100, in subjects with Pulmonary Hypertension (PH) accompanying Interstitial Lung Disease (ILD), PH-ILD
What is the current status of trial NCT05867914?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 5 participants. The study started on 2023-12-04. Estimated completion is 2024-03-29.
What conditions does trial NCT05867914 study?
This clinical trial studies the following conditions: Lung Diseases, Interstitial, Hypertension, Pulmonary.
What interventions are being tested in trial NCT05867914?
The interventions under investigation include: Inhaled Nitric Oxide (iNO) (DEVICE).
Who is sponsoring clinical trial NCT05867914?
This trial is sponsored by Third Pole Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05867914 being conducted?
This trial has 3 study locations across Florida, Ohio, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Diseases, Interstitial
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05867914's enrollment target sits among peer trials
5 11th of 10 the lowest of 10 other Lung Diseases, Interstitial trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Diseases, Interstitial trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation
RECRUITING · NA
-
Oxygen Savings With Administered Oxygen and High Flow Ambient Air At Rest
COMPLETED · NA
-
Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1)
COMPLETED · NA
-
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
RECRUITING · Phase 3
-
Dorothy P. and Richard P. Simmons Center for ILD Research Registry
RECRUITING
-
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI